By Maggie Fick and Bhanvi Satija

LONDON (Reuters) -Novo Nordisk’s new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues a bidding war with U.S. rival Pfizer.

The drugmaker will release third quarter results on Wednesday, the first for Mike Doustdar who was tasked in August with turning around the Danish company’s fortunes.

Novo, facing tougher competition from U.S. rival Eli Lilly in the lucrative obesity market, has seen its stock slide 50% this year, a sharp turn around from a peak in 2024 when it had been Europe’s most valuable listed firm.

ALL EYES ON NEW CEO

Novo’s earnings come just two weeks after controlling shareholder, the Novo Nordisk Foundation, seized control of the board, accusing its leadership of moving too slowl

See Full Page